|
Pathologies
|
Code
|
Name
|
Target
|
Pharm. Ref.
|
Biology
|
PDF |
Epilepsy |
P-001 |
Fast sodium channel inhibition |
Sodium channels |
Tetrodotoxin |
Action Potential genesis and propagation |
|
Hungtington’s Disease |
P-001 |
Fast sodium channel inhibition |
Sodium channels |
Tetrodotoxin |
Action Potential genesis and propagation |
|
Hyperactivity and Attention Deficit Disorders |
P-001 |
Fast sodium channel inhibition |
Sodium channels |
Tetrodotoxin |
Action Potential genesis and propagation |
|
Multiple Sclerosis |
P-001 |
Fast sodium channel inhibition |
Sodium channels |
Tetrodotoxin |
Action Potential genesis and propagation |
|
Neuropathic Pain |
P-001 |
Fast sodium channel inhibition |
Sodium channels |
Tetrodotoxin |
Action Potential genesis and propagation |
|
Pain |
P-001 |
Fast sodium channel inhibition |
Sodium channels |
Tetrodotoxin |
Action Potential genesis and propagation |
|
Amyotrophic Lateral Sclerosis |
P-002 |
AMPA-mediated synaptic transmission |
AMPA/Kainate receptors |
NBQX |
Glutamatergic synaptic transmission |
|
Epilepsy |
P-002 |
AMPA-mediated synaptic transmission |
AMPA/Kainate receptors |
NBQX |
Glutamatergic synaptic transmission |
|
Stroke |
P-002 |
AMPA-mediated synaptic transmission |
AMPA/Kainate receptors |
NBQX |
Glutamatergic synaptic transmission |
|
Alzheimer’s Disease |
P-003 |
NMDA receptors competitive antagonist |
NMDA receptors |
D-AP5 |
Long-Term Potentiation |
|
Hungtington’s Disease |
P-003 |
NMDA receptors competitive antagonist |
NMDA receptors |
D-AP5 |
Long-Term Potentiation |
|
Parkinson’s Disease |
P-003 |
NMDA receptors competitive antagonist |
NMDA receptors |
D-AP5 |
Long-Term Potentiation |
|
Schizophrenia |
P-003 |
NMDA receptors competitive antagonist |
NMDA receptors |
D-AP5 |
Long-Term Potentiation |
|
Anxiety |
P-004 |
GABA-A receptors - Network Excitability |
GABA-A receptors |
Bicuculline |
Epileptiform activity |
|
Epilepsy |
P-004 |
GABA-A receptors - Network Excitability |
GABA-A receptors |
Bicuculline |
Epileptiform activity |
|
Sleep Disorders |
P-004 |
GABA-A receptors - Network Excitability |
GABA-A receptors |
Bicuculline |
Epileptiform activity |
|
Anxiety |
P-005 |
Neurosteroids / GABA-A receptors |
GABA-A receptors |
Ganaxolone |
Allosteric modulation of GABA-A |
|
Epilepsy |
P-005 |
Neurosteroids / GABA-A receptors |
GABA-A receptors |
Ganaxolone |
Allosteric modulation of GABA-A |
|
Sleep Disorders |
P-005 |
Neurosteroids / GABA-A receptors |
GABA-A receptors |
Ganaxolone |
Allosteric modulation of GABA-A |
|
Anxiety |
P-006 |
Inhibition of phasic GABA-A receptors |
Phasic GABA-A receptors |
Gabazin (SR-95531) |
GABA-A receptor-mediated fast synaptic transmission |
|
Epilepsy |
P-006 |
Inhibition of phasic GABA-A receptors |
Phasic GABA-A receptors |
Gabazin (SR-95531) |
GABA-A receptor-mediated fast synaptic transmission |
|
Sleep Disorders |
P-006 |
Inhibition of phasic GABA-A receptors |
Phasic GABA-A receptors |
Gabazin (SR-95531) |
GABA-A receptor-mediated fast synaptic transmission |
|
Addiction |
P-007 |
DHPG - induced LTD |
mGluR1 & mGluR5 receptors |
DHPG |
LTD induced by mGluR1/mGluR5 activation |
|
Anxiety |
P-007 |
DHPG - induced LTD |
mGluR1 & mGluR5 receptors |
DHPG |
LTD induced by mGluR1/mGluR5 activation |
|
Epilepsy |
P-007 |
DHPG - induced LTD |
mGluR1 & mGluR5 receptors |
DHPG |
LTD induced by mGluR1/mGluR5 activation |
|
Neurodegeneration |
P-007 |
DHPG - induced LTD |
mGluR1 & mGluR5 receptors |
DHPG |
LTD induced by mGluR1/mGluR5 activation |
|
Pain |
P-007 |
DHPG - induced LTD |
mGluR1 & mGluR5 receptors |
DHPG |
LTD induced by mGluR1/mGluR5 activation |
|
Stroke |
P-007 |
DHPG - induced LTD |
mGluR1 & mGluR5 receptors |
DHPG |
LTD induced by mGluR1/mGluR5 activation |
|
Cognitive Disorders |
P-008 |
AMPA/kainate receptors-mediated excitotoxicity |
AMPA/kainate receptors |
Kainate |
Excitotoxicity |
|
Epilepsy |
P-008 |
AMPA/kainate receptors-mediated excitotoxicity |
AMPA/kainate receptors |
Kainate |
Excitotoxicity |
|
Pain |
P-008 |
AMPA/kainate receptors-mediated excitotoxicity |
AMPA/kainate receptors |
Kainate |
Excitotoxicity |
|
Stroke |
P-008 |
AMPA/kainate receptors-mediated excitotoxicity |
AMPA/kainate receptors |
kainate |
Excitotoxicity |
|
Cognitive Disorders |
P-009 |
L-type calcium channels / Synaptic Transmission |
L-type VDCC |
Nifedipine |
Modulation of synaptic transmission by VDCC |
|
Depression |
P-009 |
L-type calcium channels / Synaptic Transmission |
L-type VDCC |
Nifedipine |
Modulation of synaptic transmission by VDCC |
|
Epilepsy |
P-009 |
L-type calcium channels / Synaptic Transmission |
L-type VDCC |
Nifedipine |
Modulation of synaptic transmission by VDCC |
|
Stroke |
P-009 |
L-type calcium channels / Synaptic Transmission |
L-type VDCC |
Nifedipine |
Modulation of synaptic transmission by VDCC |
|
Alzheimer’s Disease |
P-010 |
Cholinergic transmission - Alzheimer's Disease |
Acetylcholinesterase |
Physostigmine (Eserine) |
Cholinergic modulation of glutamate neurotransmission |
|
Cognitive Disorders |
P-010 |
Cholinergic transmission - Alzheimer's Disease |
Acetylcholinesterase |
Physostigmine (Eserine) |
Cholinergic modulation of glutamate neurotransmission |
|
Dementia |
P-010 |
Cholinergic transmission - Alzheimer's disease |
Acetylcholinesterase |
Physostigmine (Eserine) |
Cholinergic modulation of glutamate neurotransmission |
|
Hyperactivity and Attention Deficit Disorders |
P-010 |
Cholinergic transmission - Alzheimer's Disease |
Acetylcholinesterase |
Physostigmine (Eserine) |
Cholinergic modulation of glutamate neurotransmission |
|
Alzheimer’s Disease |
P-011 |
NMDA & nicotinic receptors / Alzheimer's & Parkinson's Diseases |
NMDA & nicotinic receptors |
Memantine |
Long-Term Potentiation / Memory |
|
Dementia |
P-011 |
NMDA & nicotinic receptors / Alzheimer's & Parkinson's Diseases |
NMDA & nicotinic receptors |
Memantine |
Long-Term Potentiation / Memory |
|
Parkinson’s Disease |
P-011 |
NMDA & nicotinic receptors / Alzheimer's & Parkinson's Diseases |
NMDA & nicotinic receptors |
Memantine |
Long-Term Potentiation / Memory |
|
Alzheimer’s Disease |
P-012 |
H3 histamine receptor-dependent depression in Dentate Gyrus |
H3 histamine receptor |
R-alpha-methylhistamine |
Pre-synaptic H3 receptor |
|
Anxiety |
P-012 |
H3 histamine receptor-dependent depression in Dentate Gyrus |
H3 histamine receptor |
R-alpha-methylhistamine |
Pre-synaptic H3 receptor |
|
Cognitive Disorders |
P-012 |
H3 histamine receptor-dependent depression in Dentate Gyrus |
H3 histamine receptor |
R-alpha-methylhistamine |
Pre-synaptic H3 receptor |
|
Epilepsy |
P-012 |
H3 histamine receptor-dependent depression in Dentate Gyrus |
H3 histamine receptor |
R-alpha-methylhistamine |
Pre-synaptic H3 receptor |
|
Hyperactivity and Attention Deficit Disorders |
P-012 |
H3 histamine receptor-dependent depression in Dentate Gyrus |
H3 histamine receptor |
R-alpha-methylhistamine |
Pre-synaptic H3 receptor |
|
Obesity |
P-012 |
H3 histamine receptor-dependent depression in Dentate Gyrus |
H3 histamine receptor |
R-alpha-methylhistamine |
Pre-synaptic H3 receptor |
|
Parkinson’s Disease |
P-012 |
H3 histamine receptor-dependent depression in Dentate Gyrus |
H3 histamine receptor |
H3 histamine receptorR-alpha-methylhistamine |
Pre-synaptic H3 receptor |
|
Schizophrenia |
P-012 |
H3 histamine receptor-dependent depression in Dentate Gyrus |
H3 histamine receptor |
R-alpha-methylhistamine |
Pre-synaptic H3 receptor |
|
Sleep Disorders |
P-012 |
H3 histamine receptor-dependent depression in Dentate Gyrus |
H3 histamine receptor |
R-alpha-methylhistamine |
Pre-synaptic H3 receptor |
|
Anxiety |
P-013 |
Histamine receptors mediated increase of CA1 pyramidal neurons firing |
H1 and H2 histamine receptors |
Histamine |
CA1 pyramidal neurons spontaneous activity |
|
Cognitive Disorders |
P-013 |
Histamine receptors mediated increase of CA1 pyramidal neurons firing |
H1 and H2 histamine receptors |
Histamine |
CA1 pyramidal neurons spontaneous activity |
|
Pain |
P-013 |
Histamine receptors mediated increase of CA1 pyramidal neurons firing |
H1 and H2 histamine receptors |
Histamine |
CA1 pyramidal neurons spontaneous activity |
|
Sleep Disorders |
P-013 |
Histamine receptors mediated increase of CA1 pyramidal neurons firing |
H1 and H2 histamine receptors |
Histamine |
CA1 pyramidal neurons spontaneous activity |
|
Addiction |
P-014 |
mGluR2-mediated depression of synaptic transmission at MPP synapses |
mGluR2 receptors |
DCG-IV |
Pre-synaptic mGluR2 receptors |
|
Anxiety |
P-014 |
mGluR2-mediated depression of synaptic transmission at MPP synapses |
mGluR2 receptors |
DCG-IV |
Pre-synaptic mGluR2 receptors |
|
Obsessive-Compulsive Disorders |
P-014 |
mGluR2-mediated depression of synaptic transmission at MPP synapses |
mGluR2 receptors |
DCG-IV |
Pre-synaptic mGluR2 receptors |
|
Cognitive Disorders |
P-015 |
Dopamine-induced increase of synaptic transmission and plasticity |
D1/D5 dopamine receptors |
SCH23390 |
Dopaminergic modulation of synaptic transmission |
|
Parkinson’s Disease |
P-015 |
Dopamine-induced increase of synaptic transmission and plasticity |
D1/D5 dopamine receptors |
SCH23390 |
Dopaminergic modulation of synaptic transmission |
|
Epilepsy |
P-016 |
Model of 4-AP-induced Epilepsy |
K+ channel |
Phenytoin / Carbamazepine |
In vitro Epilepsy model |
|
Epilepsy |
P-017 |
Model of low-magnesium-induced Epilepsy |
NMDA receptor |
Phenytoin / Carbamazepine |
In vitro Epilepsy model |
|
Epilepsy |
P-018 |
Model of bicuculline-induced Epilepsy |
GABA-A receptor |
Somatostatin |
In vitro model of Epilepsy |
|
Epilepsy |
P-019 |
Model of cholinergic-induced epilepsy |
GABA-A / M1muscarinic receptors |
diazepam |
In vitro Epilepsy model |
|